DexCom Inc. (DXCM)
DexCom Statistics
Share Statistics
DexCom has 390.77M shares outstanding. The number of shares has increased by 1.32% in one year.
Shares Outstanding | 390.77M |
Shares Change (YoY) | 1.32% |
Shares Change (QoQ) | -2.53% |
Owned by Institutions (%) | 90.07% |
Shares Floating | 385.48M |
Failed to Deliver (FTD) Shares | 189 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 8.81M, so 2.26% of the outstanding shares have been sold short.
Short Interest | 8.81M |
Short % of Shares Out | 2.26% |
Short % of Float | 2.28% |
Short Ratio (days to cover) | 2.53 |
Valuation Ratios
The PE ratio is 54.61 and the forward PE ratio is 43.93. DexCom's PEG ratio is -39.32.
PE Ratio | 54.61 |
Forward PE | 43.93 |
PS Ratio | 7.8 |
Forward PS | 4.2 |
PB Ratio | 14.97 |
P/FCF Ratio | 49.89 |
PEG Ratio | -39.32 |
Enterprise Valuation
DexCom Inc. has an Enterprise Value (EV) of 49.93B.
EV / Earnings | 86.65 |
EV / Sales | 12.38 |
EV / EBITDA | 59.39 |
EV / EBIT | 83.21 |
EV / FCF | 79.16 |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 1.2.
Current Ratio | 1.47 |
Quick Ratio | 1.28 |
Debt / Equity | 1.2 |
Total Debt / Capitalization | 54.6 |
Cash Flow / Debt | 0.39 |
Interest Coverage | 31.58 |
Financial Efficiency
Return on equity (ROE) is 0.27% and return on capital (ROIC) is 10.53%.
Return on Equity (ROE) | 0.27% |
Return on Assets (ROA) | 0.09% |
Return on Capital (ROIC) | 10.53% |
Revenue Per Employee | $395,392.16 |
Profits Per Employee | $56,490.2 |
Employee Count | 10,200 |
Asset Turnover | 0.62 |
Inventory Turnover | 2.89 |
Taxes
Income Tax | 132.8M |
Effective Tax Rate | 0.19 |
Stock Price Statistics
The stock price has increased by -29.73% in the last 52 weeks. The beta is 1.29, so DexCom's price volatility has been higher than the market average.
Beta | 1.29 |
52-Week Price Change | -29.73% |
50-Day Moving Average | 84.36 |
200-Day Moving Average | 86.36 |
Relative Strength Index (RSI) | 47.1 |
Average Volume (20 Days) | 3.62M |
Income Statement
In the last 12 months, DexCom had revenue of 4.03B and earned 576.2M in profits. Earnings per share was 1.42.
Revenue | 4.03B |
Gross Profit | 2.47B |
Operating Income | 600M |
Net Income | 576.2M |
EBITDA | 840.7M |
EBIT | 600M |
Earnings Per Share (EPS) | 1.42 |
Balance Sheet
The company has 606.1M in cash and 2.53B in debt, giving a net cash position of -1.92B.
Cash & Cash Equivalents | 606.1M |
Total Debt | 2.53B |
Net Cash | -1.92B |
Retained Earnings | 1.6B |
Total Assets | 6.48B |
Working Capital | 1.37B |
Cash Flow
In the last 12 months, operating cash flow was 989.5M and capital expenditures -358.8M, giving a free cash flow of 630.7M.
Operating Cash Flow | 989.5M |
Capital Expenditures | -358.8M |
Free Cash Flow | 630.7M |
FCF Per Share | 1.56 |
Margins
Gross margin is 61.14%, with operating and profit margins of 14.88% and 14.29%.
Gross Margin | 61.14% |
Operating Margin | 14.88% |
Pretax Margin | 17.58% |
Profit Margin | 14.29% |
EBITDA Margin | 20.85% |
EBIT Margin | 14.88% |
FCF Margin | 15.64% |
Dividends & Yields
DXCM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 1.65% |
FCF Yield | 1.88% |
Analyst Forecast
The average price target for DXCM is $99, which is 15.2% higher than the current price. The consensus rating is "Buy".
Price Target | $99 |
Price Target Difference | 15.2% |
Analyst Consensus | Buy |
Analyst Count | 17 |
Stock Splits
The last stock split was on Jun 13, 2022. It was a forward split with a ratio of 4:1.
Last Split Date | Jun 13, 2022 |
Split Type | forward |
Split Ratio | 4:1 |
Scores
Altman Z-Score | 6.38 |
Piotroski F-Score | 6 |